Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% growth year-over-year compared to $19.1 million in 2024 [28] - For Q4 2025, net revenue was $12.4 million, reflecting an 11% growth over Q3 2025, with a strong quarter-over-quarter demand growth of 15.5% in Q4 [28] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025, significantly lowering interest costs [34][38] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology commercial product, more than doubled its sales in 2025 compared to 2024, with expectations of continued growth driven by new patient starts and increased market penetration [6][28] - The company anticipates achieving peak market share for LOQTORZI by 2028, targeting $175 million in annualized revenues, which would represent about 70% market share of the $250 million total addressable market [7][32] Market Data and Key Metrics Changes - The NCCN guidelines for nasopharyngeal carcinoma (NPC) were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which has stimulated growth in 2025 [29] - The company is focusing on expanding its reach in the community segment, where off-label immuno-oncology (IO) treatments persist [29] Company Strategy and Development Direction - Coherus has transitioned from a biosimilar company to an innovative oncology company, focusing on overcoming immune resistance in cancer through strategic acquisitions and product development [4][6] - The company is investing in its pipeline, particularly in tagmokitug and Casdozokitug, with multiple clinical readouts expected in 2026 [10][27] - The strategic partnership with Johnson & Johnson for tagmokitug is seen as a validation of the company's scientific competency and a pathway to further collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits compared to chemotherapy alone [30] - The company is well-positioned financially, with sufficient funding to support operations and pipeline advancements through 2026 and into 2027 [9][39] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [30] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, reflecting a 35% reduction [34] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales performance, which could provide additional financial support [36] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in 2026 as the duration of therapy for existing patients increases [46] Question: What are the promotional sensitivities of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [49] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [51][52] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [57] Question: How will data from ongoing trials be disclosed? - Data will be reported as it becomes available, either aligned with congress submission deadlines or through corporate disclosures [62]

Core Insights - BioNTech and OncoC4 presented promising data for gotistobart (BNT316/ONC-392), a Treg depletion candidate, showing significant overall survival benefits in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) compared to standard chemotherapy [1][4][5] Company Overview - BioNTech is a biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases, leveraging advanced immunotherapy techniques and a diverse oncology pipeline [9] - OncoC4 is a late clinical-stage biopharmaceutical company engaged in developing novel biologicals for cancer treatment, with a strategic collaboration with BioNTech for gotistobart [14] Clinical Trial Insights - The PRESERVE-003 trial is a two-stage Phase 3 study evaluating gotistobart as a monotherapy against standard chemotherapy in sqNSCLC patients who have progressed on prior treatments [5] - In the non-pivotal stage, 45 patients received gotistobart, while 42 received docetaxel, with a 12-month overall survival rate of 63.1% for gotistobart versus 30.3% for docetaxel [2][4] - The ongoing pivotal stage aims to enroll approximately 500 patients across multiple countries, focusing on overall survival as the primary endpoint [5] Treatment Efficacy - Gotistobart has not yet reached a median overall survival at nearly 15 months of follow-up, while docetaxel showed a median overall survival of 10 months [2][4] - The treatment with gotistobart reduced the risk of death by 54% compared to docetaxel, indicating a significant clinical advantage [2][4] Safety Profile - The safety profile of gotistobart was manageable, with 42.2% of patients experiencing grade ≥3 treatment-related adverse events compared to 48.8% in the docetaxel group [2][4] Regulatory Status - Gotistobart has received Fast Track Designation from the FDA for treating metastatic NSCLC patients whose disease progressed on prior anti-PD-(L)1 therapy, highlighting its potential as a novel treatment option [4][6]

Coherus Oncology Conference Call Summary Company Overview - **Company**: Coherus Oncology - **Ticker**: NasdaqGM:CHRS - **Industry**: Oncology Key Points Company Value Proposition - Coherus Oncology's value proposition is summarized as "drugs, data, and deals" [2][28] - The company focuses on innovative oncology treatments, particularly in the PD-1 space with LOQTORZI and emerging therapies like CHS-114 and casdozokitug [2][3] Product Pipeline - **LOQTORZI**: A foundational PD-1 product approved for nasopharyngeal cancer, expected to generate revenue and expand its label with ongoing studies [4][6] - **CHS-114**: A highly selective Treg depleter, recognized as an important therapeutic approach, with studies in colorectal and gastric cancers [3][4][19] - **Casdozokitug**: An anti-IL-27 therapy being developed for liver and lung cancers, showing promising early data [3][21] Market Potential - The combined pipeline addresses a market opportunity of approximately **$30 billion** in the U.S. across multiple cancer indications [6] - LOQTORZI is projected to reach a revenue range of **$150-$200 million** by mid-2028, with a growth rate of **10%-15%** in recent quarters [9][10] Clinical Studies and Data - Ongoing studies for CHS-114 in colorectal and gastric cancers, with data expected in **2026** [5][19] - Casdozokitug has shown a **60%** tumor shrinkage rate and a **38%** overall response rate in initial studies, significantly outperforming standard care [24] Strategic Partnerships and Licensing - Coherus has a strong track record of divesting biosimilar assets, raising nearly **$800 million** and paying off **$480 million** in debt [25][26] - The company is focused on collaborations to enhance patient survival through combination therapies, leveraging its PD-1 and other products with partners [26][27] Scientific Innovations - LOQTORZI's mechanism involves high-affinity binding at the FG loop, leading to significant T cell signaling advantages [8] - CHS-114 targets CCR8 on Treg cells in the tumor microenvironment, aiming to enhance immune response against tumors [11][14] Future Outlook - Coherus is optimistic about the outcomes of ongoing studies and the potential for expanding its pipeline into additional cancer types [20][28] - The company is actively seeking to validate its pipeline through partnerships and collaborations, which will also help offset clinical trial costs [27][28] Additional Insights - The company emphasizes the importance of Treg depletion in treating "cold" tumors, which represent **70%** of certain cancer types [12][19] - The strategic acquisition of Surface Oncology for **$65 million** has positioned Coherus for innovative oncology advancements [26] This summary encapsulates the key insights from the Coherus Oncology conference call, highlighting the company's strategic direction, product pipeline, market potential, and scientific innovations.